Saturday, May 21, 2022
HomeLatest Pharma-NewsPfizer to provide UK with additional 2.5M treatment courses of Paxlovid

Pfizer to provide UK with additional 2.5M treatment courses of Paxlovid

December 22, 2021: ” Pfizer Inc. announced an additional agreement with the United Kingdom (UK) government to supply an additional 2.5 million treatment courses of its investigational candidate PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), subject to local authorization.

This is in addition to the 250,000 treatment courses previously contracted by the UK Government, pending authorization and recommendation for use, bringing the full amount of treatment courses to 2.75 million.

- Advertisement -

“Final data from our Phase 2/3 trial in high-risk participants confirmed the overwhelming efficacy of PAXLOVID in reducing the risk of hospitalization by nearly 90% compared to placebo when treated within both three and five days of symptom onset and no deaths.

We are pleased that the UK government recognizes the importance of this potential treatment option,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer.

“As we continue to combat the virus, we are in discussions with governments around the world to help ensure we get this potential treatment to patients as quickly as possible, subject to authorization or approval.”

In anticipation of the potential for regulatory authorization or approval, Pfizer initiated
manufacturing of PAXLOVID earlier this year and expects to produce up to 80 million courses of treatment by the end of 2022, with 30 million treatment courses available in the first half of the year. 

Our Commitment to Equitable Access 
Pfizer is committed to working toward equitable access to PAXLOVID for all people, aiming to deliver well-tolerated and effective antiviral therapeutics as soon as possible and at an affordable price.

If authorized or approved, during the pandemic, Pfizer will offer our oral antiviral therapy through a tiered pricing approach based on the income level of each country to promote equity of access across the globe.

High and upper-middle income countries will pay more than lower income countries. 
 
Pfizer continues to invest up to approximately $1 billion to support the manufacturing and distribution of PAXLOVID, including exploring potential contract manufacturing options.

It has entered into agreements with multiple countries and has initiated bilateral outreach to approximately 100 countries around the world.

Additionally, Pfizer has signed a voluntary license agreement with the Medicines Patent Pool (MPP) for its oral antiviral treatment to help expand access, pending country regulatory authorization or approval, in 95 low- and middle-income countries that account for approximately 53% of the world’s population.  

About PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) 
PAXLOVID is an investigational SARS-CoV-2 protease inhibitor antiviral therapy.

It was developed to be administered orally so that, if authorized or approved, it can be prescribed at the first sign of infection or, pending clinical success of the rest of the EPIC development program and subject to regulatory authorization, at first awareness of an exposure – potentially helping patients avoid severe illness (which can lead to hospitalization and death) or avoid disease development following contact with a household member who contracts COVID-19.

Nirmatrelvir [PF-07321332], which originated in Pfizer laboratories, is designed to block the activity of the SARS-CoV-2 3CL (or main) protease, an enzyme that the coronavirus needs to replicate.

Co-administration with a low dose of ritonavir helps slow the metabolism, or breakdown, of nirmatrelvir in order for it to remain active in the body for longer periods of time at higher concentrations to help combat the virus.  
 
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication.

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. 
 
Current variants of concern can be resistant to treatments that are focused on the spike protein expressed on the surface of the SARS-CoV-2 virus, due to the mutations in this region. PAXLOVID, however, works intracellularly on the protease of the SARS-CoV-2 virus by inhibiting viral replication.

Nirmatrelvir has shown consistent in vitro antiviral activity against the previously identified variants of concerns (i.e., alpha, beta, delta, gamma, lambda, and mu).

In addition, nirmatrelvir potently inhibited the main protease associated with Omicron in an in vitro biochemical assay.

This indicates nirmatrelvir’s potential to maintain robust antiviral activity against Omicron. Additional in vitro antiviral studies with this variant are underway. 
 
If authorized or approved, PAXLOVID will be administered at a dose of 300 mg (two 150 mg tablets) of nirmatrelvir with one 100 mg tablet of ritonavir, given twice-daily for five days.

One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course.”

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provide-united-kingdom-additional-25-million
 

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular